Unique Wealth LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Unique Wealth LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 347 shares of the company’s stock after buying an additional 13 shares during the period. Unique Wealth LLC’s holdings in Eli Lilly and Company were worth $314,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of LLY. Franklin Street Advisors Inc. NC grew its holdings in Eli Lilly and Company by 1,420.5% in the second quarter. Franklin Street Advisors Inc. NC now owns 28,449 shares of the company’s stock worth $25,757,000 after purchasing an additional 26,578 shares during the period. Davis Investment Partners LLC grew its holdings in Eli Lilly and Company by 8.4% in the second quarter. Davis Investment Partners LLC now owns 904 shares of the company’s stock worth $857,000 after purchasing an additional 70 shares during the period. CFM Wealth Partners LLC grew its holdings in Eli Lilly and Company by 19.9% in the second quarter. CFM Wealth Partners LLC now owns 9,403 shares of the company’s stock worth $8,513,000 after purchasing an additional 1,563 shares during the period. Tyche Wealth Partners LLC grew its holdings in Eli Lilly and Company by 11.1% in the second quarter. Tyche Wealth Partners LLC now owns 4,454 shares of the company’s stock worth $4,032,000 after purchasing an additional 445 shares during the period. Finally, Acorn Creek Capital LLC lifted its stake in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. Acorn Creek Capital LLC now owns 927 shares of the company’s stock worth $840,000 after purchasing an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the sale, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Insiders have sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 in the last quarter. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have commented on LLY shares. Argus upped their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, August 5th. Morgan Stanley reiterated an “overweight” rating and set a $1,023.00 price objective on shares of Eli Lilly and Company in a research note on Friday, July 5th. Finally, JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $956.88.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $9.46 during trading on Friday, reaching $922.12. 2,364,894 shares of the stock traded hands, compared to its average volume of 3,096,824. The company has a market capitalization of $876.39 billion, a price-to-earnings ratio of 135.81, a P/E/G ratio of 1.81 and a beta of 0.41. The business has a fifty day simple moving average of $878.93 and a two-hundred day simple moving average of $805.16. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $966.10.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.